CD34-cell selection according to the good manufacturing practice.

被引：0
|
作者：
Arseniev, L
Schwender, J
Drexler, K
Schmidt-Thomssen, A
Goudeva, L
Heuft, HG
Sykora, RW
Ganser, A
Hertenstein, B
机构：
[1] Hannover Med Sch, Dept Hematol, D-3000 Hannover, Germany
[2] Hannover Med Sch, Dept Pediat Hematol, D-3000 Hannover, Germany
[3] Hannover Med Sch, Dept Transfus Med, D-3000 Hannover, Germany
[4] Cytonet Hannover GmbH, Hannover, Germany
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5131
引用
收藏
页码：320B / 320B
页数：1
相关论文
共 50 条
  • [31] Autologous blood cell transplantation in multiple myeloma:: Impact of CD34+ cell selection vs non-selection.
    Remes, K
    Itälä, M
    Kauppila, M
    Pelliniemi, TT
    Rajamäki, A
    BONE MARROW TRANSPLANTATION, 1999, 23 : S138 - S138
  • [32] Peptide epitopes of anti-CD34 monoclonal antibodies which function as release reagents for CD34+ cell selection.
    Tseng-Law, J
    Szalay, P
    Guillermo, R
    Van Epps, D
    EXPERIMENTAL HEMATOLOGY, 1998, 26 (08) : 777 - 777
  • [33] Autologous peripheral blood precursor cell transplantation after CD34 selection
    Tichelli, A
    Gratwohl, A
    Bargetzi, M
    Nissen, C
    Wernli, M
    Herrmann, R
    Orth, B
    Signer, E
    Speck, B
    SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1996, 126 (06) : 201 - 206
  • [34] T cell depleted allogeneic PBSC transplantation using CD34+cell selection.
    Bensinger, W
    Cornetta, K
    Carabasi, M
    Yanovich, S
    Hughes, T
    Skikne, B
    Chabannon, C
    Singhal, S
    Mills, B
    BLOOD, 2000, 96 (11) : 199A - 199A
  • [35] Autologous stem cell transplantation in multiple myeloma: The effect of CD 34+ cell selection.
    Patriarca, F
    Fanin, R
    Damiani, D
    Silvestri, F
    Geromin, A
    Sperotto, A
    Cerno, M
    Grimaz, S
    Stocchi, R
    Baccarani, M
    BLOOD, 1998, 92 (10) : 370B - 370B
  • [36] VARIATION OF BONE MARROW CD34+ CELL SUBSETS IN MYELODYSPLASTIC SYNDROMES ACCORDING TO WHO TYPES
    Reis, S. C.
    Traina, F.
    Metze, K.
    Saad, S. T. O.
    Lorand-Metze, I.
    NEOPLASMA, 2009, 56 (05) : 435 - 440
  • [37] CD3/CD19-Depleted Natural Killer Cell Production under Good Manufacturing Practices
    Williams, S. M.
    Sumstad, D.
    Kadidlo, D. M.
    Curtsinger, J. M.
    Miller, J. S.
    McKenna, D. H.
    TRANSFUSION, 2016, 56 : 49A - 49A
  • [38] Natural killer cell production under good manufacturing practice conditions to treat cancer patients
    Perez-Martinez, A.
    Santamaria, S.
    Varela, M. A.
    Leivas, A.
    Valentin, J.
    Fernandez, L.
    Martinez, J.
    HUMAN GENE THERAPY, 2013, 24 (12) : A165 - A166
  • [39] Regulatory requirements in the good manufacturing practice production of an epithelial cell graft for ocular surface reconstruction
    Sheth-Shah, Radhika
    Vernon, Amanda J.
    Seetharaman, Shankar
    Neale, Michael H.
    Daniels, Julie T.
    REGENERATIVE MEDICINE, 2016, 11 (03) : 307 - 320
  • [40] CD34(+) cell selection and purging in haematopoietic stem cell transplantation: technical report of a single centre
    Pekel, A.
    Samur, Z.
    Yesillik, S.
    Akay, R.
    Erdem, G.
    Karadurmus, N.
    Ozaydin, S.
    Ozturk, M.
    Ataergin, S.
    Kuzhan, O.
    Arpaci, F.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S256 - S256
12345